Courtois 10mg Davipharm is used to reduce LDL-cholesterol (2 blisters x 14 tablets)

Rosuvastatin increases the number of LDL receptors on the surface of the cell in the liver, thus increasing the absorption and the LDL fire and inhibiting the VLDL synthesis in the liver, thus reducing the VLDL and LDL components.

pharmacokinetics

Rosuvastatin absorbed completely from the digestive tract. Absolute bioavailability is about 20%. Peak concentration in plasma is about 5 hours after drinking.

distribution:

Rosuvastatin widely distributed in the liver is the main place for cholesterol and LDL-C clearance. The distribution of rosuvastatin is about 134 L. About 90% of rosuvastatin combined with plasma proteins.

transformation:

Rosuvastatin metabolizes mainly by Cytochrom P450 ISOENZYM CYP2C9. Selling plasma waste time is about 19 hours. The waste time does not increase when using higher doses.

excretion:

About 90% of rosuvastatin dose is eliminated in a constant form (including the active ingredient that is absorbed and not absorbed) and the rest is excreted into urine. About 5% are excreted into unchanged urine.

According to the pharmacokinetic research in the US in Asians, the ability to absorb Rosuvastatin average in Asians has increased by nearly 2 times more than white people.

Notify the physician the unwanted effects when using the drug.

Be cautious when using

need to be very careful when taking the drug for patients in the following cases:

Muscle impact

It is necessary to consider when taking drugs belonging to the statin group for patients with risk factors leading to muscle damage. The statin group is at risk of causing harmful reactions to the muscle system such as muscle atrophy, muscle inflammation, especially for patients with risk factors such as patients over 65 years old, patients with untreated thyroid diseases, patients with kidney disease. Need to closely monitor the harmful reactions during drug use.

Patients should immediately report to the doctor to treat signs or symptoms of muscle pain, fatigue, fever, dark urine, nausea or vomiting during the use of the drug.

Consider monitoring Creatin Kinase (CK)

Before treatment, CK tests should be conducted in the following cases: impaired renal function, hypothyroidism, self -history or money, family history with genetic diseases, a history of muscle disease due to the use of statin or fibrat before, a history of liver disease and/or drinking lots of alcohol, elderly patients (> 70 years old) with risk factors for muscle patterns, special patients and some patients. In these cases, the benefits/risks should be considered and monitor patients clinically when treated with statin. If the results of CK test> 5 times the upper limit of normal levels, do not start treatment with statin.

During statin treatment, patients need to notify when there are muscle manifestations such as muscle pain, muscle stiffness, muscle weakness, ... When these manifestations, patients need to do CK test to take appropriate interventions.

Effects on the liver:

Like other HMG-CoA Reductase inhibitors, caution should be used when using rosuvastatin in patients with severe alcoholism and/or a history of liver disease.

Recommended the liver enzyme test before starting statin treatment and in case of clinical indications for testing later. Rosuvastatin should be stopped or reduced if serum transaminase concentration is 3 times the upper limit of normal levels.

Simultaneous use with anticoagulant drugs:

Be cautious when using rosuvastatin along with anticoagulant drugs because it has the ability to cause prolombin/Inr -type Coumarin -style.

The effect of the drug on driving and operating machinery

studies to determine the effects of rosuvastatin on driving and operating the machine has not been performed. When driving or operating the machine should note that dizziness may occur during treatment.

Use drugs for women during pregnancy and lactation

HMG-CAA Reductase inhibitors are contraindicated for pregnant and lactating women.

Rosuvastatin is only used for women of reproductive age when certainly not pregnant and has been notified about the possibility of endanger.

If a patient is pregnant while taking the drug, the medication should be stopped immediately and the patient should be known about the potential danger to the fetus.

Drug interaction

Increased risk of muscle lesions: When using rosuvastatin simultaneously with the following drugs:

cyclosporin: simultaneously use rosuvastatin with cyclosporin, increasing blood concentration of rosuvastatin, so it should be used rosuvastatin at a dose of 5 mg/day.

Vitamin K antagonists: Like other HMG-COA Reductase inhibitors, when starting to treat or increase the dose of rosuvastatin in patients treated simultaneously with vitamin K antagonists (such as warfarin) can increase the Inr value. Stopping or reducing the dose of rosuvastatin may reduce the INR. In such cases, the Inr value should be monitored.

Gemfibrozil: Like other HMG-CoA Reductase inhibitors, simultaneously use rosuvastatin with gemfibrozil, increasing blood rosuvastatin levels. Should avoid simultaneous use or if necessary to coordinate, do not use more than 10 ng rosuvastatin/day.

Antimeter: Use Rosuvastatin simultaneously with aluminum antacids and Magnesi Hydroxid, reducing about 50% of the plasma rosuvastatin levels. When taking antacids 2 hours after using rosuvastatin, the plasma rosuvastatin levels will be reduced less. The clinical correlation of this interaction is still unclear.

erythromycin: simultaneously use rosuvastatin with erythromycin, reducing 20% ​​AUC and 30% cmax of rosuvastatin. This interaction may be due to erythromycin increasing intestinal motility.

Oral contraceptives/hormone replacement therapy (HRT): simultaneous use of rosuvastatin with contraceptive pill that increases 26% AUC of Ethinyl Estradiol and 34% AUC of Norgestrel. It should be noted that increasing the concentration of these substances in plasma when choosing oral contraceptives. There is no pharmacokinetic data on patients using rosuvastatin and HRT simultaneously and therefore cannot exclude the same possibility. However, the combination has been widely used in women in clinical trials and has been well tolerated.

Protease inhibitors of HIV and hepatitis C (HCV): The simultaneous use of statin lipid medications with HIV and hepatitis C (HCV) can increase the risk of muscle damage, the most serious is muscle pattern, kidney damage leading to kidney failure and can be fatal.